Unknown

Dataset Information

0

Lenalidomide in follicular lymphoma.


ABSTRACT: Lenalidomide is an immunomodulatory drug approved in the United States for use with rituximab in patients with relapsed/refractory follicular lymphoma. We reviewed data from trials addressing the safety and efficacy of lenalidomide alone and in combination with rituximab as a first-line therapy and as a treatment of patients with relapsed/refractory follicular lymphoma. Lenalidomide-rituximab has been demonstrated to be an effective chemotherapy-free therapy that improves upon single-agent rituximab and may become an alternative to chemoimmunotherapy.

SUBMITTER: Flowers CR 

PROVIDER: S-EPMC7290094 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4622102 | biostudies-literature
| S-EPMC8095143 | biostudies-literature
| S-EPMC7391139 | biostudies-literature
| S-EPMC7907727 | biostudies-literature
| S-EPMC5123195 | biostudies-literature
| S-EPMC6225348 | biostudies-literature
| S-EPMC5789808 | biostudies-literature
| S-EPMC4380740 | biostudies-literature
| S-EPMC8379261 | biostudies-literature
| S-EPMC6594227 | biostudies-literature